title: T cell receptor-therapy in HBV-related hepatocellularcarcinoma.
abstract: Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific antigen and thus be targeted by adoptively transferred HBV-specific TCR redirected T cells.
authors.affiliation: Program Emerging infectious Diseases; Duke-NUS Medical School ; Singapore, Singapore ; Singapore Institute for Clinical Sciences; ASTAR ; Singapore, Singapore ; School of Immunity and Infection; College of Medical and Dental Science; University of Birmingham ; Edgbaston, Birmingham, UK.
authors.forename: Antonio
authors.initials: A
authors.lastname: Bertoletti
authors.affiliation: Hepatology Unit; University Hospital of Pisa ; Pisa, Italy.
authors.forename: Maurizia
authors.initials: M
authors.lastname: Brunetto
authors.affiliation: Division of Infection & Immunity; Institute of Immunity & Transplantation; University College London ; London, UK.
authors.forename: Mala K
authors.initials: MK
authors.lastname: Maini
authors.affiliation: General Medicine; Liver and Digestive Disease Unit; University Hospital of Pisa ; Pisa, Italy.
authors.forename: Ferruccio
authors.initials: F
authors.lastname: Bonino
authors.affiliation: Institute of Child Health & Great Ormond Street Hospital; University College London ; London, UK.
authors.forename: Waseem
authors.initials: W
authors.lastname: Qasim
authors.affiliation: Division of Infection & Immunity; Institute of Immunity & Transplantation; University College London ; London, UK.
authors.forename: Hans
authors.initials: H
authors.lastname: Stauss
keywords: CHB, Chronic hepatitis B; HBV; SCID, Severe combined immunodeficiency; T cell therapy; hepatocellularcarcinoma